

Arsenic trioxide nanoparticles inhibit acute promyelocytic leukemia cell proliferation and induce apoptosis *via* PTEN/AKT signalling pathway.

Yalin Wang¹, Yi Dong², Yingmin Liu¹, Ziling Liu^{1*}

¹Cancer Center, the First Hospital of Jilin University, Jilin, P.R. China

²Department of Oncology, the Affiliated Hospital of Cheng De Medical College, Hebei, P.R. China

Abstract

Background: Arsenic Trioxide (As₂O₃) is a FDA-approved agent for the treatment of Acute Promyelocytic Leukemia (APL). But the high-toxicity is a bottleneck of the effect of As₂O₃.

Methods: In our previous work, we made a novel nanoparticle formulation of As₂O₃. The aim of the present study was to preliminary study the possible mechanisms of the antitumor effect of As₂O₃ nanoparticles on NB4 cells. We examined the proliferation and apoptosis of NB4 cells incubated with the As₂O₃ or As₂O₃ nanoparticles. Protein levels of p-PTEN, p-AKT, Bax, caspase-3, caspase-9 and AIF of NB4 cells after using As₂O₃ nanoparticles and traditional As₂O₃ were determined by Western blotting analysis.

Results: *In vitro* cytotoxicity test showed that the inhibition rate and apoptosis level of NB4 cells treated with As₂O₃ nanoparticles was much higher than that of traditional As₂O₃. Moreover, As₂O₃ nanoparticles resulted in a more significant increase in p-PTEN expression and a greater reduction in p-Akt expression compared with traditional As₂O₃.

Conclusions: Our findings indicated the obvious anticancer effect of As₂O₃ nanoparticles and demonstrate the possible mechanism of its therapeutic potential. The results provide a foundation for the future clinical studies of As₂O₃ nanoparticles in APL patients.

Keywords: Arsenic trioxide, Acute promyelocytic leukemia, Nanoparticles, PTEN, Akt.

Accepted on January 30, 2018

Introduction

Acute Promyelocytic Leukemia (APL) is the M3 subtype of acute myelogenous leukemia and cytogenetically is characterized by a translocation of chromosomes 15 and 17, which results in the fusion between Retinoic Acid Receptor α (*RAR* α) and the Promyelocytic Leukemia (*PML*) gene. APL is always accompanied with severe bleeding tendency and disseminated intravascular coagulation. The first-line treatment of APL was chemotherapy. More than 80% of patients treated with all-trans retinoic acid along with chemotherapy can achieve a prolonged remission. Relapsed patients are often treated with arsenic trioxide successfully [1].

Arsenic Trioxide (As₂O₃) is the primary component of arsenic (pishuang), a kind of traditional Chinese medicine. In the early 1970's, some Chinese physicians from Harbin Medical University recognized arsenic as an effective ingredient for leukemia treatment. In 1996 and 1997, notable effect was reported for the use of As₂O₃ in APL [2]. The Food and Drug Administration (FDA) approved As₂O₃ as frontline treatment for APL in 2000 [3]. Apart from APL, it was used in several kinds of diseases, such as Chronic Lymphocytic Leukemia (CLL), liver cancer, syphilis, psoriasis, rheumatism [4-7]. However, the toxicity of arsenic was recognised by people

gradually. The side effect of long-term chronic exposure to arsenic include hyperpigmentation of the skin, hyperkeratosis of the palms and feet, cancers of lung, bladder, prostate, kidney, liver as well as neuropathy, leucopenia, encephalopathy, peripheral vascular diseases and diabetes. Consequently, it faded out from clinical applications owing to its toxicity and carcinogenic properties [5].

Nanoparticles are becoming an emerging treatment modality for cancer. The advantages of nanoparticles are delivering anticancer drugs to the tumor, the ability to enhance permeability, bioavailability and efficacy as well as reduction or reversion of multidrug resistance. Owing to the unique features of tumor vasculature, the "Enhanced Permeability and Retention (EPR) effect" allows nanoparticles to extravasate into extravascular spaces and increase the drug concentration inside tumor tissues more than free drugs [8]. Nowadays, most nanoparticles can selectively target on cancer cells, reducing the undesirable side effects of conventional chemotherapy, and therefore improving the efficacy of patients [9,10].

The As₂O₃ nanoparticles were prepared with the so-gel method. In this study, the *in vitro* effect of As₂O₃ nanoparticles on NB4 cells was assessed by evaluating MTT analysis, mitochondrial membrane potential and flow cytometric

analysis. Furthermore, we explore the possible mechanism of by detecting the protein levels of p-PTEN, p-AKT, Bax, caspase-3, caspase-9 and AIF.

Methods

Cell culture

NB4 cells were a kind gift from Dr. Jifan Hu at Stanford University Medical School (Palo Alto, CA, USA) for research in the laboratory of the First Affiliated Hospital of Jilin University (Changchun, China). NB4 cells were cultured in Iscove's Modified Dulbecco's Medium (Gibco-BRL, Grand Island, NY, USA) containing heat inactivated 10% Fetal Bovine Serum (FBS) (Hanzhou Sijiqing Biological Engineering Materials Co., Ltd. Hanzhou, China) along with 100 U/ml of penicillin and 0.1 mg/ml of streptomycin in an atmosphere of 5% CO₂ and 100% humidity.

Preparation of As₂O₃ nanoparticles

The As₂O₃ nanoparticles were synthesized with the sol-gel method as we previously described [11]. The preparation method was as follows: As₂O₃ powder and hydrochloric acid were mixed and stirred for 1030 min. Ethanol was then added, the solution was stirred at 5060°C for 2030 min and sonicated for 5 min. Finally, distilled water was added, and the mixture was sonicated for another 1020 min.

MTT analysis

The inhibitory effect of As₂O₃ (Institute for Drug Control of the Ministry of Health of China) and As₂O₃ nanoparticles was estimated by MTT assay. There were 3 groups, which were control, As₂O₃ and As₂O₃ nanoparticles. NB4 cells were seeded on 96 well plates in quadruplicate at a density of 2×10^5 /well in 100 μ l. As₂O₃ and As₂O₃ nanoparticles (4 different final concentrations: 0.5, 1, 2, 4 μ mol/L) were added at the right time according to the group setting. After 24, 48 and 72 h of treatment, the cells were incubated for 3-4 h with MTT (Changchun Biotech Co., Ltd. Changchun, China) and lysed with acidified isopropanol. Absorbance was measured at 570 nm. The inhibition rate was calculated using the following formula: Inhibition rate = ((absorbance value of control group - absorbance value of test group) / absorbance value of control group) \times 100%. All experiments were repeated three times.

Hoechst 33342/PI staining

Cellular nuclear was stained with Hoechst 33342 (Hoechst Pharmaceuticals) and Propidium Iodide (PI) to observe the cellular apoptosis or necrosis situation by fluorescence microscopy. Briefly, 1×10^6 NB4 cells were incubated with 3 μ mol/L As₂O₃ and As₂O₃ nanoparticles for 24 h. Cells were washed with PBS, suspended with new fresh medium, double stained with Hoechst 33342/PI and visualised by fluorescence microscopy.

Flow cytometric analysis

NB4 cells were treated with 1.5 μ mol/L and 3.0 μ mol/L As₂O₃, As₂O₃ nanoparticles against untreated control for 24 h at 37°C with 5% CO₂. After treatment, 1×10^5 NB4 cells were stained with Annexin V/Propidium Iodide Apoptosis Detection Assay kit (Beyotime Institute of Biotechnology Co., Shanghai, China). The apoptosis of NB4 cells in 3 groups were examined by flow cytometry (FCM; FACSCalibur™, BD Biosciences, San Jose, CA, USA).

Mitochondrial membrane potential

NB4 cells were incubated with 1.5 and 3 μ mol/L As₂O₃ and As₂O₃ nanoparticles for 24 h. 1×10^6 NB4 cells were stained with Rhodamine 123 (Sigma). Cells were washed with PBS, suspended with new fresh medium. Mean Fluorescence Intensity (MFI) was on behalf of Mitochondrial Membrane Potential (MMP) and examined the MFI in each group with Flow cytometric.

Western blotting analysis

The expression level of p-PTEN, p-AKT, Bax, caspase-3, caspase-9 and AIF was determined by Western Blotting analysis in 3 groups (control, As₂O₃, As₂O₃ nanoparticles). The extracted total protein was loaded on SDS-polyacrylamide gel. The protein was separated after electrophoresis and transferred to a nitrocellulose membrane. Membrane was blocked with 5% non-fat dry milk at room temperature for 2 h and incubated with primary antibody: p-PTEN, p-AKT, caspase-3 rabbit mAb, caspase-9 mouse mAb (Cell Signaling Technology, Danvers, MA), Bax rabbit mAb (Proteintech Group, Chicago, America), AIF rabbit mAb and β -actin mouse mAb (Beyotime, Shanghai, China). The membrane was washed with PBST thrice for 10 min each time and then incubated with horseradish peroxidase (HRP)-labeled goat-anti-rabbit or goat-anti-mouse secondary antibody (Beyotime, Shanghai, China) at room temperature for 1 h. Membranes were washed for 3 times with PBST. Exposure to Kodak® X-omat LS film (Eastman Kodak Company, New Haven, CT) after incubating with enhanced chemiluminescence (ECL) substrate (Bio-Rad, Hercules, CA, USA). Densitometry was applied with Kodak® 1D image analysis software (Eastman Kodak Company).

Results

Inhibitory effect of As₂O₃ nanoparticles on NB4 cell proliferation

The inhibitory effect of As₂O₃ nanoparticles and As₂O₃ on NB4 cell proliferation was examined by MTT assay. As shown in Figure 1, the drugs had time and dose dependent anti-proliferative effects on NB4 cells. Furthermore, the inhibitory effect of As₂O₃ nanoparticles was much higher than traditional As₂O₃.

Arsenic trioxide nanoparticles inhibit acute promyelocytic leukemia cell proliferation and induce apoptosis via PTEN/AKT signalling pathway




Figure 1. Effect of As_2O_3 nanoparticles and As_2O_3 on NB4 cells proliferation. NB4 cells were incubated with drugs for: (A) 24 h; (B) 48 h; (C) 72 h; (D) Inhibitory effect of As_2O_3 nanoparticles on NB4 cell proliferation at 24 h, 48 h and 72 h.

Results of Hoechst 33342/PI staining

NB4 cells were incubated with 3 $\mu mol/L$ As_2O_3 nanoparticles or As_2O_3 for 24 h. Hoechst 33342/PI double staining was performed to observe the cell nuclear apoptosis or necrosis situation. Apoptotic cells were stained blue by Hoechst 33342 with pyknosis and stained red by PI with chromatin condensation. As shown in Figure 2, apoptosis was present after being treated with As_2O_3 nanoparticles or As_2O_3 .




Figure 2. Morphology of NB4 cells being stained by Hoechst 33342/PI under fluorescence microscopy. A (a) Control; B (b) 3 $\mu mol/L$ As_2O_3 ; C (c) As_2O_3 nanoparticles (bar=50 μm).

As_2O_3 nanoparticles induce NB4 cell apoptosis

Both As_2O_3 nanoparticles and As_2O_3 can induce NB4 cells apoptosis. Figure 3 showed a dose-dependent inducing apoptosis effect of As_2O_3 nanoparticles and As_2O_3 on NB4 cells. Furthermore, As_2O_3 nanoparticles had higher inhibition ability than As_2O_3 .

Mitochondrial membrane potential

The mean fluorescence intensity level of control group is 1313.67 MFI. Meanwhile, the mean fluorescence intensity level of 1.5 $\mu mol/L$ and 3.0 $\mu mol/L$ As_2O_3 is 1085.09 MFI and 881.20 MFI. What's more, the mean fluorescence intensity level of 1.5 $\mu mol/L$ and 3.0 $\mu mol/L$ As_2O_3 nanoparticles is

911.05 MFI and 371.17 MFI. As_2O_3 nanoparticles can significantly decrease the mean fluorescence intensity level of NB4 cells than As_2O_3 (Figure 4).




Figure 3. Apoptosis of NB4 cells after being treated with As_2O_3 nanoparticles or As_2O_3 . NB4 cells were treated as follows with an apoptosis rate: (A) Control, 0.95%; (B) 1.5 $\mu mol/L$ As_2O_3 , 1.8%; (C) 1.5 $\mu mol/L$ As_2O_3 nanoparticles, 8.96%; (D) 3.0 $\mu mol/L$ As_2O_3 , 21.25%; (E) 3.0 $\mu mol/L$ As_2O_3 nanoparticles, 37.79%.




Figure 4. Mitochondrial membrane potential of NB4 cells was examined by flow cytometry after being stained by Rhodamine123. (A) Control group; (B) 1.5 $\mu mol/L$ As_2O_3 ; (C) 1.5 $\mu mol/L$ As_2O_3 nanoparticles; (D) 3 $\mu mol/L$ As_2O_3 ; (E) 3 $\mu mol/L$ As_2O_3 nanoparticles; (F) The quantitative mitochondrial membrane potential levels of all groups; * $P < 0.05$; ** $P < 0.01$.

Protein levels of PTEN, Akt and Bax of NB4 cells treated with As_2O_3 nanoparticles

Protein levels of PTEN, Akt and Bax of NB4 cells incubated with As_2O_3 and As_2O_3 nanoparticles were detected by Western blotting. Both As_2O_3 and As_2O_3 nanoparticles can decrease the protein expression level of PTEN and p-Akt at the concentration of 1.5 $\mu mol/L$ and 3.0 $\mu mol/L$, and the drugs increase the expression of p-PTEN and Bax.

Meanwhile, the expression of PTEN and p-Akt were much lower in the As_2O_3 nanoparticles group than in the As_2O_3 group, as well as the levels of p-PTEN and Bax were much higher in the former group than the latter with a dose-dependent manner (Figure 5).

Protein levels of caspase-3, caspase-9 and AIF of NB4 cells treated with As₂O₃ nanoparticles

At the concentration of 1.5 μmol/L, the protein levels of caspase-3 and caspase-9 were much higher in As₂O₃ nanoparticles group than As₂O₃ group. While, the levels were lower in 3.0 μmol/L As₂O₃ nanoparticles group than 3.0 μmol/L As₂O₃ group (Figure 5).

We further examined the level of AIF of NB4 cells. Figure 5 showed that the AIF level was higher in the As₂O₃ nanoparticles group than the group of As₂O₃ solution.




Figure 5. Protein levels of PTEN, p-PTEN, p-Akt, Bax, caspase-3, caspase-9 and AIF of NB4 cells following treatment of As₂O₃ nanoparticles or As₂O₃ for 24 h. NB4 cells were treated as follows: (1) Control; (2) 1.5 μmol/L As₂O₃; (3) 1.5 μmol/L As₂O₃ nanoparticles; (4) 3 μmol/L As₂O₃; (5) 3 μmol/L As₂O₃ nanoparticles.

Discussion

As₂O₃, a kind of traditional Chinese medicine, had been approved as frontline treatment for APL by FDA for many years. It could also be used in other solid cancer, such as liver cancer, prostate cancer, cervical cancer and breast cancer [9,12-18]. However, its clinical application is somehow limited owing to its high toxicity to the normal tissues. Therefore, different formulations of As₂O₃ with higher antitumor efficacy and lower toxicity are needed to be further studied.

Several kinds of As₂O₃ nanoparticles have been reported. Qian developed a scFvCD44v6-decorated PEG-PDLLA nanoparticle, which scFv-As-NP could target delivery of As to CD44v6-positive tumor cells PANC-1 [19]. The As₂O₃ nanoparticles with better antitumor efficacy can highly improve the drug concentration in tumor site but not normal tissues owing to the EPR effect and its better targeting effect. Nanobin encapsulation of As₂O₃ improves the pharmacokinetics and antitumor efficacy of As₂O₃ in a murine model of breast cancer and lymphoma [20,21].

In our previous study, we prepared small-sized (<10 nm and ~40 nm) As₂O₃ nanoparticles with sol-gel method [11]. Herein, the superiority efficacy of proliferationinhibition and apoptosisinduction effects *in vitro* of As₂O₃ nanoparticles than As₂O₃ were further confirmed by evaluating MTT assay, apoptosis detection with flow cytometric assay, mitochondrial membrane potential, p-PTEN, p-AKT, Bax, caspase-3, caspase-9 and AIF protein levels. A much smaller dose of As₂O₃ nanoparticles can achieve a good antitumor effect,

which would reduce the systemic toxic side effects with a reduction of toxicity.

As₂O₃ has a property of proliferation inhibition of APL cell, such as NB4 cell lines. As₂O₃ nanoparticles, even at a low concentration of 2 μmol/L (Figure 1), can significantly inhibit the growth of NB4 cells. As₂O₃ nanoparticles can also induce apoptosis of NB4 cells in a dose-dependent manner (Figure 3). PTEN/Akt signalling pathway is involved in antitumor process [22,23]. PTEN is closely associated with PI3K/Akt pathway. It is a negative regulator of PI3K/Akt pathway owing to its IP3 phosphatase activity, which influences the cell proliferation and apoptosis [24,25]. And PI3K/Akt pathway has been proposed to inhibit Bax translocation from cytoplasm to mitochondria [26]. The inactivation of Akt can induce Bax translocate to mitochondria, which can decrease the mitochondrial membrane potential to induce apoptosis. In our present study, both As₂O₃ nanoparticles and As₂O₃ can increase the protein level of p-PTEN and decrease the level of p-Akt (Figure 5). Here we demonstrated that the induce-apoptosis of As₂O₃ nanoparticles and As₂O₃ is connected with PTEN and Akt. As₂O₃ and 1.5 μmol/L As₂O₃ nanoparticles could increase caspase-3 and caspase-9 protein expression. However, the 3 μmol/L As₂O₃ nanoparticles could improve the protein expression of AIF but not caspase-3 and caspase-9. We demonstrate that the apoptosis of As₂O₃ and As₂O₃ nanoparticles in a lower concentration is related with a caspase-dependent mitochondrial apoptosis pathway, but higher concentration of As₂O₃ nanoparticles induce NB4 cells apoptosis by a caspase-independent mitochondrial apoptosis pathway.

Conclusions

In conclusion, As₂O₃ nanoparticles can inhibit proliferation and induce apoptosis of APL cells, and the induce-apoptosis effect was correlated with PTEN/Akt signaling pathway. As₂O₃ nanoparticles are selective and potential anti-APL agents which could inhibit proliferation and induce apoptosis of APL cells with high efficacy.

Acknowledgement

This work was supported by the Department of Science and Technology of Jilin Province, China (Grant Number 20150204005YY).

Conflicts of Interest

The authors have no conflicts of interest to declare.

Ethical Statement

This article does not contain any studies with human participants or animals performed by any of the authors.

References

1. Licht JD. Acute promyelocytic leukemia-weapons of mass differentiation. *N Engl J Med* 2009; 360: 928-930.

Arsenic trioxide nanoparticles inhibit acute promyelocytic leukemia cell proliferation and induce apoptosis via PTEN/AKT signalling pathway

2. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. *Blood* 2008; 111: 2505-2515.
3. Antman KH. Introduction: the history of arsenic trioxide in cancer therapy. *Oncologist* 2001; 6: 1-2.
4. Bairey O, Vanichkin A, Shpilberg O. Arsenic-trioxide-induced apoptosis of chronic lymphocytic leukemia cells. *Int J Lab Hematol* 2010; 32: 77-85.
5. Anam A, Scarlet Xiaoyan W, Lucy G. Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers. *J Biomed Res* 2017.
6. Tian C, Gao P, Zheng Y. Redox status of thioredoxin-1 (TRX1) determines the sensitivity of human liver carcinoma cells (HepG2) to arsenic trioxide-induced cell death. *Cell Res* 2008; 18: 458-471.
7. Diepart C, Karroum O, Magat J. Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors. *Cancer Res* 2012; 72: 482-490.
8. Wang X, Yang L, Chen ZG. Application of nanotechnology in cancer therapy and imaging. *CA Cancer J Clin* 2008; 58: 97-110.
9. Jadhav V, Ray P, Sachdeva G. Biocompatible arsenic trioxide nanoparticles induce cell cycle arrest by p21(WAF1/CIP1) expression via epigenetic remodeling in LNCaP and PC3 cell lines. *Life Sci* 2016; 148: 41-52.
10. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. *Nat Rev Drug Discov* 2008; 7: 771-782.
11. Dong X, Ma N, Liu M. Effects of As₂O₃ nanoparticles on cell growth and apoptosis of NB4 cells. *Exp Ther Med* 2015; 10: 1271-1276.
12. Zhang KZ, Zhang QB, Zhang QB. Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model. *J Hematol Oncol* 2014; 7: 28.
13. Ma Y, Wang J, Liu L. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-kappaB. *Cancer Lett* 2011; 301: 75-84.
14. Chen FY, Yi JW, Gu ZJ. Inorganic phosphate-triggered release of anti-cancer arsenic trioxide from a self-delivery system: an in vitro and in vivo study. *Nanoscale* 2016; 8: 6094-6100.
15. Kang YH, Yi MJ, Kim MJ. Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: reactive oxygen species-mediated poly (ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria. *Cancer Res* 2004; 64: 8960-8967.
16. Sun RC, Board PG, Blackburn AC. Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells. *Mol Cancer* 2011; 10: 142.
17. Thomas-Schoemann A, Batteux F, Alexandre J. A new strategy to target regulatory T cells in solid tumors. *Oncoimmunology* 2013; 2: e23338.
18. Si L, Jiang F, Li Y. Induction of the mesenchymal to epithelial transition by demethylation- activated microRNA-200c is involved in the anti-migration/invasion effects of arsenic trioxide on human breast cancer cells. *Mol Carcinog* 2015; 54: 859-869.
19. Qian C, Wang Y, Chen Y. Suppression of pancreatic tumor growth by targeted arsenic delivery with anti-CD44v6 single chain antibody conjugated nanoparticles. *Biomaterials* 2013; 34: 6175-6184.
20. Ahn RW, Chen F, Chen H. A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. *Clin Cancer Res* 2010; 16: 3607-3617.
21. Ahn RW, Barrett SL, Raja MR. Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo. *PLoS One* 2013; 8: e58491.
22. Zhang X, Jia S, Yang S. Arsenic trioxide induces G2/M arrest in hepatocellular carcinoma cells by increasing the tumor suppressor PTEN expression. *J Cell Biochem* 2012; 113: 3528-3535.
23. McCubrey JA, Steelman LS, Abrams SL. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. *Adv Enzyme Regul* 2006; 46: 249-279.
24. Dahia PL, Aguiar RC, Alberta J. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. *Hum Mol Genet* 1999; 8: 185-193.
25. Chow LM, Baker SJ. PTEN function in normal and neoplastic growth. *Cancer Lett* 2006; 241: 184-196.
26. Tsuruta F, Masuyama N, Gotoh Y. The phosphatidylinositol 3-kinase (PI3K)-Akt pathway suppresses Bax translocation to mitochondria. *J Biol Chem* 2002; 277: 14040-14047.

***Correspondence to**

Ziling Liu
Cancer Center
The First Hospital of Jilin University
Jilin
P.R. China